Acute kidney injury
102 results
1 - 100
Prediction tool for chronic kidney disease following acute kidney injury- No difference in acute kidney injury but more delirium with cefepime instead of piperacillin-tazobactam (ACORN)
- Timing of RRT in critically ill patients with acute kidney injury: verdict still out
- Early initiation of RRT does not improve mortality in patients with sepsis and severe acute kidney injury
- Decreased risk of postoperative acute kidney injury with continuous amino acid infusion during and after cardiac surgery
- No mortality benefit, increased risk of acute kidney injury with addition of beta-lactam to usual therapy for MRSA bacteremia
- Testosterone does not increase major adverse cardiac events, but does increase risk of AFib, PE, acute kidney injury, and arrhythmia (TRAVERSE)
- For patients with chronic kidney disease, prehydration prior to contrast-enhanced computed tomography is unnecessary
- Improved mortality with early initiation of RRT in critically ill patients
- Clinical decision rule identifies AKI patients at low risk for hydronephrosis
- Early initiation of RRT in critically ill patients with AKI does not lower 90-day mortality
- No mortality difference between early and delayed initiation of renal replacement therapy in critically ill patients with AKI
- Intraoperative hypotension but no major adverse events with continuation of perioperative RASIs
- ACE + ARB does not improve outcomes in pts with T2DM with impaired renal function (VA NEPHRON)
- No benefit from revascularization for asymptomatic renal artery stenosis (ASTRAL)
- Less renal replacement therapy with sodium bicarbonate infusion for patients with severe metabolic acidosis
- Individualized perioperative BP management reduces post-op complications
- No benefit with restrictive fluid strategy during perioperative period for major abdominal surgery
- No clear advantage to balanced crystalloids over saline; though 1 study suggests a mortality benefit in patients with sepsis
- Intensive treatment of elevated blood pressure in hospitalized patients associated with adverse events
- Final report from SPRINT: lowering SBP below 120 mm Hg decreases major adverse cardiac events and all-cause mortality
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- No differences in postoperative deaths or complications with stopping or continuing renin-angiotensin system inhibitors
- Increased mortality with K <3.5 or >4.5 in patients hospitalized with acute MI
- SBP of 120 instead of 140 in adults 75 years or older = significant benefits and some harms (SPRINT)
- Rifaximin effective in decreasing post-TIPS hepatic encephalopathy in patients with cirrhosis
- TAVR is as effective as surgical valve replacement for intermediate-risk patients with AS (PARTNER 2)
- No benefit with use of periprocedural sodium bicarbonate or acetylcysteine in patients with CKD and angiography
- Improved outcomes with complete revascularization in older adults with myocardial infarction (FIRE)
- Three-day course of inhaled amikacin is effective in preventing ventilator-associated pneumonia
- No difference with continuing vs stopping ACEIs or ARBs in adults who are undergoing major noncardiac surgery
- Intensive BP control modestly decreased the likelihood of a broad composite of CV events, but with methodologic limitations
- No benefit with balanced vs saline solution or slower vs faster rate for fluid resuscitation in ICU
- Mortality risk is similar, but complications differ with TAVI and SAVR
- No benefit to restrictive transfusion strategy for cardiac surgery patients